Solid Biosciences Inc.

Solid Biosciences Inc.

NNASDAQ:SLDB
6.48
USD
-0.36
(-5.26%)
-1.72EPS
806.54MMarket Cap
Mar 16Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
1.91
0.95
- -
- -
- -
- -
Basic EPS, GAAP
-5.03
-13.44
-17.4
-33.73
-43.64
-25.5
-10.14
-10.1
-4.83
-3.06
-1.99
-1.72
Free Cash Flow per Basic Share
-3.28
-16
-21.18
-35.16
-36.15
-16.61
-11.1
-11.86
-4.81
-2.47
-1.8
-1.6
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-31.42
-39.26
-27.58
53
26.11
23.34
28.3
10.82
6.2
3.39
2.28
3.07
Tangible Book Value per Share
-31.42
-39.26
-27.58
53
26.11
23.34
28.3
10.82
6.2
3.39
2.28
3.07
Basic Weighted Avg Shares
1
1
2
2
3
3
7
9
20
41
88
125
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
14
8
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
-530.5
-1,226.51
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
2
3
4
3
2
3
2
2
2
Net Income, GAAP
-6
-22
-52
-75
-117
-88
-72
-86
-96
-125
-174
-215
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
-530.01
-1,062.28
- -
- -
- -
- -
Working Capital
42
33
59
116
68
134
199
197
115
127
172
335
LT Debt
- -
- -
- -
1
5
3
1
26
24
21
19
17
Total Equity
-20
-38
-59
125
80
132
208
212
126
137
180
342
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-114.24
-83.24
-42.43
-40.96
-56.79
-94.57
-109.9
-76.87

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
18
18
17
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
98
105
112
Market Capitalization
708
1,050
807

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
397
395
365
Cash, Cash Equivalents & STI
381
378
349
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
30
29
30
Payables & Accruals
20
16
15
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-7.7%
11.74%
31.16%
Free Cash Flow
68.64%
24.32%
56.4%
Net Income, GAAP
53.75%
16.44%
39.8%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.64
-0.61
-0.79
-1
-3.06
2025
-0.59
-0.42
-0.48
-0.53
-1.99
2026
-0.52
-0.38
-0.36
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Alexander Gery Cumbo
Full Time Employees
121
Sector
Health technology
Industry
Biotechnology
Address
500 Rutherford Avenue Charlestown MA United States 02129
IPO Date
Jan 26, 2018
Business
Solid Biosciences Inc. (Nasdaq: SLDB) develops precision genetic medicines, primarily gene therapies, targeting rare neuromuscular and cardiac diseases. Founded in 2013 and headquartered in Charlestown, Massachusetts, the company advances a diversified pipeline that includes SGT-003, a next-generation AAV gene therapy in Phase 1/2 trials (INSPIRE and IMPACT studies) for Duchenne muscular dystrophy utilizing the proprietary AAV-SLB101 capsid; SGT-212, a dual-route administration gene therapy for Friedreich's ataxia that has received FDA Fast Track designation and IND clearance; SGT-501 for RYR2- and CASQ2-mediated catecholaminergic polymorphic ventricular tachycardia; SGT-601 for TNNT2-mediated dilated cardiomyopathy; SGT-401 for BAG3-mediated dilated cardiomyopathy; SGT-701 for RBM20-mediated dilated cardiomyopathy; and additional undisclosed cardiac programs in collaboration with Mayo Clinic, alongside platform technologies such as neuromuscular and cardiac capsid libraries, novel promoters, dual gene expression systems, and immunomodulation techniques. Solid Biosciences operates principally in the United States, serving patients with high-unmet-need genetic disorders through research, preclinical development, and clinical-stage gene transfer candidates. In recent developments, the company broadened its pipeline over the last two years to encompass multiple neuromuscular and cardiac indications beyond Duchenne muscular dystrophy, advanced SGT-003 into clinical trials with its optimized capsid, opened a second IND for the industry-first dual-route SGT-212 program, continued building next-generation capsid libraries with selections anticipated in Q4 2025, and licensed its AAV-SLB101 capsid to 15 academic and corporate partners; earlier, in 2022, it acquired AavantiBio to create a combined entity focused on neuromuscular and cardiac rare diseases, supported by a $75 million private placement financing.

Company News

  • Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

  • Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

  • Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates

  • Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich's Ataxia

  • Solid Biosciences (SLDB) Expected to Announce Quarterly Earnings on Monday

  • Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026

  • Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations

  • Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

  • Solid Biosciences to Participate at Upcoming Investor Conferences

  • Solid Biosciences: The Bull Case Is No Longer Just Duchenne

  • Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

  • Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Solid Biosciences to Participate at Upcoming Investor Conferences

  • Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

  • Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

  • Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy